Dinutuximab
Dinutuximab
Definition
A chimeric mouse/human monoclonal antibody with potential antineoplastic activity. Dinutuximab binds to the ganglioside GD2 and induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity against GD2-expressing tumor cells. GD2 is overexpressed in malignant melanoma, neuroblastoma, osteosarcoma, and small cell carcinoma of the lung.
Also known as Ch 14.18UTC, Ch14.18, DINUTUXIMAB, Dinutuximab Beta, MOAB Ch14.18, monoclonal antibody Ch14.18, Qarziba, Unituxin — per NCIT
Also identified as
- NCIT NCIT:C1570 per NCIT
- SCTID 724036009 per RXNORM
- SCTID 763590003 per RXNORM
- UNII 7SQY4ZUD30 per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| Neuroblastoma | may treat | MEDRT · Public domain (U.S. Government work) |
Organ Effects
| Organ | Side effect / interaction | Source |
|---|---|---|
| Nervous system | may treat a disease of this organ | DERIVED · CC BY 4.0 |
1 entry above is marked DERIVED: Atlas Médico inferred it by combining two sourced claims, and no source asserts this link directly. Treat it as a navigation aid, not as a clinical statement.